Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 2,351 shares at $27.50 ($65K) on 2024-07-31, disclosed to the SEC on 2024-08-02.
Scheduled sale ($65k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.50 | 649 | $18K | 27.6% |
| 2 | $27.51 | 1,702 | $47K | 72.4% |
| Total | $27.51 avg | 2,351 | $65K | 100% |
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |